RxDoctor Payments Data

Emily Tamadonfar, MD

Neurology · Los Angeles, CANPI 1689105777

Payments from drug & device makers

$23,099in general payments, 2019–2025

Across 30 payments — averaging $769.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$11K
  • Medtronic$11K
  • Abbott$890
  • AbbVie$99
  • Acorda Therapeutics, Inc$93
  • Amneal Pharmaceuticals LLC$47
  • plus $30 from 1 others

What the payments were for

  • Grants$20,00087%
  • Travel & lodging$1,7598%
  • Food & beverage$1,2495%
  • Education$910%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,099 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$69,370
Medicare patients
219
Services billed
992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa56$44,765
Rasagiline Mesylate32$7,637
Carbidopa-Levodopa ErCarbidopa/Levodopa98$5,518
Carbidopa-LevodopaCarbidopa/Levodopa181$5,206
AmantadineAmantadine Hcl22$1,721
Quetiapine Fumarate17$439
Ropinirole Hcl12$406
Pregabalin14$376
Propranolol Hcl27$340
Gabapentin35$285
Mirtazapine14$277
Escitalopram Oxalate36$258
Primidone15$251
Ropinirole ErRopinirole Hcl12$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$47$44,76556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →